The global viral vector manufacturing market accounted for $227.78 million in 2018 and is expected to reach $1,013.00 million by 2026 growing at a CAGR of 18.3% during the forecast period 2019 to 2026. The increasing prevalence of target diseases and disorders, a rising number of clinical studies and availability of funding for gene therapy development, and potential applications in novel drug delivery approaches are some of the factors propelling the market growth. However, the excessive cost of gene therapies and possible mutagenesis impede the market.
Viral Vector Manufacturing comprises the generation of these vectors, which then have to be purified in order to meet the quality attributes required for further use as gene delivery systems. Viral or non-viral vector methods are used the inefficient transfer of the therapeutic gene into the target cells. Viral vectors used in gene therapy include adenovirus, lentivirus, retrovirus, and adeno-associated viral (AAV). Non-viral vectors generally depend on delivery of plasmid DNA.
Vectors are living organisms that transmit infectious diseases between humans and from animals to humans. There are several types of viral vectors that are used to deliver nucleic acids into the genetic makeup of cells, including retrovirus, lentivirus, adenovirus, adeno-associated virus, and herpes simplex virus. Viral vectors are highly valued to transfer genetic material into target cells and therefore are explored as vehicles in various therapeutic areas.
Key factors expected to drive growth of the global viral vector manufacturing market is increasing funding in the biopharmaceutical production. In addition, increasing healthcare expenditure, growing ageing population, technological advancement in genetic engineering sector, growing interest in new space of research i.e. gene therapy applications are some other factors expected to drive growth of the global viral vector manufacturing market. Furthermore, increasing accessibility for healthcare facilities, growing demand for effective disease treatments, growing incidence of chronic diseases are some other factors expected to drive growth of the global target market over the forecasted period. However, high cost of manufacturing and gene therapies are factors expected to hamper growth of the global viral vector manufacturing market to a certain extent in the forecast period.
Major players in the viral vector manufacturing process are focusing on enhancing its product portfolio by developing advance technologies and focusing on conducting various clinical trial and R&D activities. In addition, established manufacturers are collaborating with other local players in order to expand geographical presences as well as cater the growing demand for effective treatment mode of diseases. These are some of the trends witnessed in the target market, currently.
Some of the key players profiled in the Viral Vector Manufacturing Market include Spark Therapeutics, Uniqure, Kaneka Eurogentec, Regenxbio, Finvector Vision Therapies, Novasep, Massbiologics, Merck KGaA, Cobra Biologics, Fujifilm Holdings Corporation, Lonza, Brammer Bio, Oxford Biomedica and Thermo Fisher Scientific Inc.
Segmentation by type:
- Adeno-associated virus (AAV)
- Other Viral Vectors (includes Lentiviral Vectors, Herpes Simplex Virus Vectors, etc.)
Segmentation by diseases:
- Infectious Disease
- Genetic Disorders
Segmentation by application:
- Gene Therapy
Segmentation by end user:
- Biotech companies
- Research Institutes
Segmentation by region:
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
What our report offers:
- Market share assessments for the regional and country level segments
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic analysis: Drivers and Constraints, Product/Technology Analysis, Porter's five forces analysis, SWOT analysis etc.
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements